Denosumab for bone diseases: translating bone biology into targeted therapy

Effects of denosumab on fracture and bone mineral density by level of kidney function

(2011) Sophie A Jamal et al.   JOURNAL OF BONE AND MINERAL RESEARCH

American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

(2011) Catherine H. Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

(2011) Daniele Santini et al.   PLoS One

Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis

(2011) Hae-Rim Kim et al.   ARTHRITIS RESEARCH & THERAPY

Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells

(2010) H. Li et al.   BLOOD

Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma

(2010) C.H. Buckle et al.   CURRENT PHARMACEUTICAL DESIGN

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

(2009) R. K. Dore et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL

(2009) Lorenz C. Hofbauer et al.   ARTHRITIS AND RHEUMATISM

RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4–Dependent Pathway

(2009) Sara Panizo et al.   CIRCULATION RESEARCH

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

(2008) Ann E. Kearns et al.   ENDOCRINE REVIEWS

RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats

(2008) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY